A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation

A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation

ABSTRACTCD40 agonism by systemic administration of CD40 monoclonal antibodies has been explored in clinical trials for immunotherapy of cancer, uncovering enormous potential, but also dosing challenges in terms of systemic toxicity. CD40-dependent activation of antigen presenting cells is dependent...

Full description

Bibliographic Details
Main Authors: Alessandro Mega, Aman Mebrahtu, Gustav Aniander, Eva Ryer, Annette Sköld, Anna Sandegren, Eva Backström Rydin, Johan Rockberg, Arne Östman, Fredrik Y. Frejd
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:mAbs
Subjects:
Cancer
CD40
immuno-oncology
microenvironment
PDGFRB
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2023.2223750

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2023.2223750

Similar Items